| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8447817 | European Journal of Cancer | 2010 | 9 Pages |
Abstract
In this manuscript the most relevant issues and pitfalls for combination drug phase I trial design are discussed. Several phase I study designs that incorporate controls to circumvent bias due to imbalances in observed background toxicity are discussed.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Paul Hamberg, Mark J. Ratain, Emmanuel Lesaffre, Jaap Verweij,